Eugene P. McFadden mainly investigates Internal medicine, Cardiology, Stent, Surgery and Myocardial infarction. His work on Coronary artery disease, Clopidogrel, ST segment and Prospective cohort study as part of general Internal medicine research is frequently linked to Risk assessment, thereby connecting diverse disciplines of science. His Cardiology study incorporates themes from Thrombosis and Radiology.
His Stent research integrates issues from Percutaneous coronary intervention, TIMI and Sirolimus. In the field of Surgery, his study on Clinical endpoint, Bare-metal stent and Randomized controlled trial overlaps with subjects such as Antibacterial agent. His Myocardial infarction research includes themes of Discontinuation, Randomization and Hazard ratio.
His primary scientific interests are in Internal medicine, Cardiology, Surgery, Myocardial infarction and Angioplasty. His work in the fields of Internal medicine, such as Coronary artery disease, Percutaneous coronary intervention, Angina and Artery, intersects with other areas such as In patient. His studies in Cardiology integrate themes in fields like Restenosis and Angiography, Radiology.
His study in Stent, Drug-eluting stent, Percutaneous and Thrombosis is carried out as part of his Surgery studies. In general Stent study, his work on Coronary stent often relates to the realm of Antibacterial agent, thereby connecting several areas of interest. Eugene P. McFadden works mostly in the field of Myocardial infarction, limiting it down to topics relating to Clinical endpoint and, in certain cases, Stroke.
Internal medicine, Cardiology, Percutaneous coronary intervention, Myocardial infarction and Surgery are his primary areas of study. His Coronary artery disease, Coronary atherosclerosis, Core laboratory and QT interval study in the realm of Internal medicine connects with subjects such as In patient. Eugene P. McFadden has researched Cardiology in several fields, including Biomarker and Percutaneous.
His Percutaneous coronary intervention research is multidisciplinary, incorporating elements of Conventional PCI, Renal function and Confidence interval. His research investigates the connection with Myocardial infarction and areas like Clinical endpoint which intersect with concerns in Stroke and Prospective cohort study. Stent is the focus of his Surgery research.
Eugene P. McFadden mostly deals with Clinical trial, Surgery, Myocardial infarction, Internal medicine and Randomized controlled trial. The concepts of his Clinical trial study are interwoven with issues in Outcome assessment, Surrogate endpoint, Medical education and Intensive care medicine. Eugene P. McFadden is interested in Stent, which is a field of Surgery.
He works in the field of Myocardial infarction, focusing on Percutaneous coronary intervention in particular. His study looks at the relationship between Internal medicine and fields such as Cardiology, as well as how they intersect with chemical problems. The various areas that Eugene P. McFadden examines in his Randomized controlled trial study include Sirolimus, Revascularization, Electrocardiography, Prospective cohort study and Subgroup analysis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions
Donald E. Cutlip;Stephan Windecker;Roxana Mehran;Ashley Boam.
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
Marco Valgimigli;Héctor Bueno;Robert A Byrne;Jean-Philippe Collet.
European Heart Journal (2018)
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.
Eugène P McFadden;Eugenio Stabile;Evelyn Regar;Edouard Cheneau.
The Lancet (2004)
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Micheal E. Bertrand;Maarten L. Simoons;Keith A.A. Fox;Lars C. Wallentin.
European Heart Journal (2002)
High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography.
Nico R. Mollet;Filippo Cademartiri;Carlos A.G. van Mieghem;Giuseppe Runza.
Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents
Andrew T.L. Ong;Eugène P. McFadden;Evelyn Regar;Peter P.T. de Jaegere.
Journal of the American College of Cardiology (2005)
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial
Elvin Kedhi;Kaiyum Sheik Joesoef;Eugene McFadden;Jochem Wassing.
The Lancet (2010)
Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World” The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry
Pedro A. Lemos;Patrick W. Serruys;Ron T. van Domburg;Francesco Saia.
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.
M. E. Bertrand;Victor Legrand;J. Boland;E. Fleck.
Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study.
Eric Bonnefoy;Frédéric Lapostolle;Alain Leizorovicz;Gabriel Steg.
The Lancet (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: